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Background
During flow-mediated vasodilatation, nitric oxide acti-
vates guanylate cyclase and the resultant increase cGMP
leads to an activation of PKGI. PKGI activates a number of
targets in the smooth muscle cell that result in smooth
muscle relaxation, including MLC phosphatase. MLC
phosphatase isolated from smooth muscle is a holoen-
zyme consisting of three subunits; a 20 kDa subunit, a 38
kDa catalytic subunit and a myosin targeting subunit
(MYPT1). MYPT1 has two isoforms that differ by the pres-
ence of a an alternatively spliced 31 bp 3' exon; exon
inclusion codes for a MYPT1 that lacks a COOH-terminus
leucine zipper (LZ-), while exon exclusion shifts the read-
ing frame and codes for a LZ+ MYPT1 isoform.
Results
We have demonstrated that PKGI mediated activation of
the MLC phosphatase requires the expression of a LZ+
MYPT1, and the relative expression of LZ+/LZ- MYPT1 iso-
forms determines the sensitivity to cGMP mediated
smooth muscle relaxation. We have also demonstrated
that in animal models of heart failure (CHF), LZ+ MYPT1
expression and the sensitivity to cGMP mediated smooth
muscle relaxation both decline. Further, activation of p42/
44 MAPK, but not p38 MAPK, signaling occurs during
CHF, and treatment with angiotensin receptor antagonists
prevents the activation of p42/44 MAPK and preserves
both normal LZ+ MYPT1 expression and normal sensitiv-
ity to cGMP mediated smooth muscle relaxation.
Conclusion
These results suggest that an AT1 receptor mediated acti-
vation of the p42/44 MAPK signaling pathway could reg-
ulate alternative splicing of the LZ MYPT1 transcript to
produce LZ+/LZ- MYPT1 isoforms. Further, a number of
investigators have demonstrated that a decrease in LZ+
MYPT1 expression is associated with heart failure, portal
hypertension and pre-eclampsia, and thus, LZ MYPT1
expression could be a marker for vascular disease.
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